Skip to content
Screener

Vericel VCEL Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$67.5MMiss by $25.2M
EPS$0.10Beat by $0.12
Revenue estimate$92.7M
EPS estimate-$0.02

Next report

Nov 5, 2026 (in a month)
Revenue estimate$78.0M
EPS estimate$0.02

Financials

Q3 2025

Income statement

See full
Revenue$67.5M+16.6%
Gross profit$49.6M+19.0%
Operating income$3.5M+240%
Net income$5.1M+663%
EPS (diluted)$0.10+600%

Balance sheet

See full
Cash & equivalents$100.4M+42.7%
Total debt$98.7M+1.2%
Total equity$321.9M+25.0%
Total assets$453.3M+16.1%

Cash flow

See full
Operating cash flow$22.1M+117%
CapEx$2.6M-86.4%
Free cash flow$19.5M+311%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.59B-23.3%
Enterprise value$1.59B-24.4%
P/E121.4×—
P/S6.1×-3.0×

Profitability

See full
Gross margin73.8%+2.3pp
Operating margin2.7%—
Net margin5.1%—

Returns & leverage

See full
Return on equity4.5%—
Debt / equity0.3×-0.1×
Current ratio4.9×+0.3×

Segments

By product

See full
M A C I Implants and kits$55.7M+24.6%
MACI implants, kits, and instruments$41.1M+29.9%
Epicel$10.4M-14.8%
Biopsy kits$652.0K+39.0%

FAQ

When did Vericel report Q3 2025 earnings?
Vericel (VCEL) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Vericel's Q3 2025 revenue and EPS?
Vericel reported revenue of $67.5M and eps of $0.10 for Q3 2025.
Did Vericel beat estimates in Q3 2025?
Revenue missed the consensus estimate of $92.7M by $25.2M. EPS beat the consensus estimate of $-0.02 by $0.12.
How did Vericel's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.6% from $57.9M a year earlier.
Where can I find Vericel's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-049880) and the 10-Q periodic report (0001628280-25-049902) directly on SEC EDGAR. The filing index links above go to sec.gov.